Market Trends of Pelvic Inflammatory Disease Therapeutics Industry
The Tetracyclines Segment is Expected to Hold the Major Share in the Pelvic Inflammatory Disease Therapeutics Market
Tetracycline drugs are expected to dominate the industry over the forecast period. The lucrative growth of the segment can be attributed to the rise in the adoption of these products due to proven efficiency in the treatment and recommendations of cephalosporin along with doxycycline, a tetracycline drug by the Centers for Disease Control and Prevention (CDC) as the first-line treatment of pelvic inflammatory disease. Rapid advancements in new product development with reduced side effects, coupled with the availability of a wide range of marketed products, are expected to fuel the market. The report published by the World Health Organization in November 2021 reported that more than 1.0 million sexually transmitted infections are acquired globally, and most of them are asymptomatic. It also reported that every year, there are an estimated 374.0 million new infections, with 1 out of 4 sexually transmitted infections: gonorrhea, chlamydia, trichomoniasis, and syphilis. Tetracyclines (tetracycline, doxycycline, minocycline, and tigecycline) are a class of drugs used to manage and cure numerous bacterial infections, according to a research report released in July 2022 under the title "Tetracycline." Tetracyclines are categorized as broad-spectrum antibiotics that suppress protein synthesis. Tetracyclines are an effective treatment for bacterial infections and their indications, mode of action, and contraindications. Such research studies will emphasize the mechanism of action, adverse event profile, and pertinent interactions important for healthcare team members involved in treating these illnesses and infected patients. Thus, such advantages provided in research studies are expected to increase the adoption of drugs, which is expected to increase the market growth.
North America Dominates the Market and it is Expected to do the Same in the Forecast Period
North America is expected to dominate the studied market throughout the forecast period. This dominance is mainly owing to rising incidences of menopausal disorders, polycystic ovary syndrome, uterine fibroids, endometriosis, trichomoniasis, HIV/AIDS, etc., due to changes in lifestyles and a rise in stress among women in the United States, which registers the highest revenue in the region. For instance, in April 2023, a report published by the Centers for Disease Control and Prevention (CDC) stated that STDs remain a significant public health concern in the country. According to the same source, Chlamydia trachomatis infection was the most prevalent notifiable sexually transmitted infection in the United States in 2021, with a total of 1,644,416 cases reported to the CDC. The CDC received reports of 710,151 different gonorrhea infections in 2021. A total of 176,713 cases of syphilis were registered in 2021 throughout all phases, including 53,767 cases of the disease's primary and secondary (P&S) stages, which are the most contagious. By raising the demand for such diseases' therapeutic processes, the country's market growth is thus anticipated to expand with the prevalence of STDs. Thus, the increasing prevalence of STIs is expected to increase the demand for therapeutics and will increase market growth.
